AKTIVITÄTEN DER ARBEITSGRUPPE "LEBER, GALLE, PANKREAS"

Durchführung folgender Studien:

Colorectale Lebermetastasen:

a. Resektabel

1. ASSO LM 1: Phase I-II Studie zur Evaluierung der Resektabilität nach neoadjuvanter Kombinationstherapie (Avastin + Xelox) bei potentiell resectablem CRC, multizentrisch-national; Beginn 01 2007
2. BOS-Trial (EORTC 40051): Phase II Studie zur Evaluierung der Machbarkeit und Verträglich einer neoadjuvanten Therapiekombination von FOLFOX6 mit Cetuximab vs FOLFOX6 mit Cetuximab und Bevacizumab bei resektablen Lebermetastasen, multizentrisch-international; Beginn 01 2007

b. Initial nicht resektabel

1. Celim-Trial: Phase II Studie zur Evaluierung des Ansprechens von FOLFOX6 mit Cetuximab vs FOLFIRI mit Cetuximab, multizentrisch-international; Beginn 2005
2. CLOCC-Trial (EORTC 40004): Phase II Studie zur Evaluierung des Überlebens von RFA+/- Leberresektion und adjuvant FOLFOX mit Bevacizumab vs FOLFOX mit Bevacizumab, multizentrisch-international; Beginn 2003 Hepatom: a. nicht resektabel 1. Precision V: Phase III Studie zur Evaluierung des Ansprechens nach DC Beads Embolisation vs konventioneller TACE, multizentrisch-international; Beginn 2005

Hepatom:

a. nicht resektabel

1. Precision V: Phase III Studie zur Evaluierung des Ansprechens nach DC Beads Embolisation vs konventioneller TACE, multizentrisch-international; Beginn 2005

VERÖFFENTLICHUNGEN DER ARBEITSGRUPPE

• Size of surgical margin does not influence recurrence rates after curative liver resection for colorectal cancer liver metastases Br J Surg 2007; in press
• Selective resection of colorectal liver metastases Eur J Surg Oncol 2007; 33:174-82
• Expression of p21Wafl/Cip1, p57Kip2 and HER2/neu in Patients with Gallbladder Cancer Anticancer Res 2007; in press
• Neoadjuvant therapy with Bevacizumab J Clin Oncol 2006;24:2592-3
• HER-2/neu protein expression in colorectal cancer BMC Cancer 2006;6:123
• Side effects during chemotherapy predict tumour response in advanced colorectal cancer Br J Cancer 2005;93:744-48
• E-Cadherin and ß-Catenin expression in normal, inflamed and cancerous gallbladder tissue Anticancer Res 2005;25:2249-54
• Interdisciplinary management of colorectal liver metastases Eur. Surg 2006; 38(2):107-11
• Treatment and outcome of intrahepatic cholangiocellular carcinoma. Am J Surgery 2005; 189(2):173-7
• Multidetector-CT (MDCT) der Leber. Radiologe. 2005;45(1):15-23
• Surgical requirements for radiological diagnostics of liver pathologies. Radiologe. 2004;44(12):1154-9
• Influence of laparoscopy on survival after surgery for gallbladder carcinoma: a matched-pair analysis Eur. Surg 2004; 36(6):350-55
• Changes in liver surgery for colorectal cancer liver metastases under neoadjuvant treatment strategies. European Surgery 2004; 36, 317-321
• p53 analysis in gallbladder cancer: comparison of gene analysis versus immunohistochemistry. Anticancer Res. 2004; 24:1201-6
• Neoadjuvant chemotherapy for resectable colorectal cancer liver metastases: Impact on magnitude of liver resection and survival. J Clin Oncol 2004 (Meeting Abstracts) 22, 3598
• Staged treatment of bilobar hepatic metastases from colorectal cancer. Eur J Surg. 2002;168(8-9):516-8
• Alternative regional treatment of resectable and unresectable liver metastases. Eur. Surg. 2002; 34, 337-340
• Long-term follow-up of surgically treated gallbladder cancer patients. Eur J Surg Oncol. 2002 Dec;28(8):857-63
• Echogenicity of liver metastases from colorectal carcinoma is an independent prognostic factor in patients treated with regional chemotherapy. Cancer. 2002 Mar 15;94(6):1753-9
• Reduction in recurrence risk for involved or inadequate margins with edge cryotherapy after liver resection for colorectal metastases. Arch Surg. 2001 Oct;136(10):1154-7
• Echogenicity of liver metastases is an independent prognostic factor after potentially curative treatment. Arch Surg. 2000 Nov;135(11):1285-90